Circulating Factor Seven Activating Protease (FSAP) in the Hyperacute Phase of Stroke

Figure 1

Flowchart. FSAP and nucleosome levels were quantified in the plasma of a subgroup of suspected stroke patients enrolled in the Treat-Norwegian Acute Prehospital Project (Treat-NASPP). In part I, all eligible ACI patients with multiple samples collected in the hyperacute phase, during hospital stay, 30 and 90 days post stroke were included. In part II, plasma from patients with ongoing stroke symptoms was used to investigate the differential diagnostic potential of FSAP. All samples were collected prior to tPA therapy. In part III, stroke patients included in part II, but with an additional plasma sample collected in the hyperacute phase (in the prehospital environment and at hospital admission), were included to characterize the dynamics of FSAP and nucleosome levels.